2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

4996 BCG042: A promising anti-LILRB4 antibody with ADCC enhancement demonstrates superior efficacy in preclinical models of monocytic AML

Peiran Li, Gao An2, Yanan Guo3, Hannah Horton4
1 Biocytogen Pharmaceuticals (Beijing), Beijing, China
2 Biocytogen Pharmaceuticals (Beijing), Beijing, China
3 Biocytogen Pharmaceuticals (Beijing), Beijing, China
4 Biocytogen, Waltham, United States

Background: Monocytic acute myeloid leukemia (AML; FAB M4/M5) is an aggressive hematologic malignancy characterized by limited response to standard therapies, including chemotherapy and hypomethylating agent (HMA) plus venetoclax combinations. LILRB4, an inhibitory receptor belonging to the leukocyte Ig-like receptor superfamily, is highly expressed on monocytic AML blasts and acts as a validated immunosuppressive driver. Its engagement with APOE activates downstream SHP-1/2 signaling and NF-κB, upregulating Arginase-1 to suppress T-cell activity and facilitate tissue infiltration. To overcome current clinical limitations, we engineered BCG042, a fully human IgG1κ monoclonal antibody with an Fc SI mutant designed to enhance effector function and accelerate targeted clearance of AML cells.

Methods: Binding kinetics and cross-reactivity were evaluated by surface plasmon resonance (SPR). Epitope binning was conducted to compare BCG042 with the clinical-stage benchmark IO-202 (h128-3 analog). Target cell binding and internalization assays were conducted on LILRB4-positive AML cell lines (THP-1 and MV-4-11) via flow cytometry. In vitro functional assays quantified APOE–LILRB4 signaling blockade, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Developability profiles were verified under various stress conditions. In vivo antitumor efficacy was evaluated in B-NDG mice bearing THP-1-Luc tumor cells, administered at 0.5, and 1 mg/kg via intraperitoneal injection every three days (Q3D×2), with tumor burden monitored by bioluminescence imaging (BLI).

Results: BCG042 binds to human LILRB4 with nanomolar affinity and cross-reacts with the cynomolgus ortholog. It demonstrates exquisite specificity with no cross-binding to human LILRB1, LILRB2, or LILRB3. Epitope binning confirmed that BCG042 shares the same epitope as the IO-202 analog. On AML cells, BCG042 exhibited strong dose-dependent binding, with EC50 values of 5.06 µg/mL in THP-1 and 13.60 µg/mL in MV-4-11 cells. Furthermore, BCG042 demonstrated cell internalization intensity comparable to that of the IO-202 analog in both cell lines. Notably, at a low dose of 1 µg/mL, BCG042 achieved superior inhibition of the APOE–LILRB4 signaling cascade compared to the IO-202 analog in vitro. BCG042 mediated robust ADCC against LILRB4+ cells without triggering ADCP or CDC, and this cytotoxic clearance was significantly amplified by the Fc-enhanced SI variant. The antibody showed high developability, maintaining excellent SEC purity and stability under thermal and low pH stresses. In vivo, BCG042 induced significant, dose-dependent tumor regression. It markedly outperformed the IO-202 analog at equivalent dosages, demonstrating potent, superior antitumor efficacy. This strong therapeutic activity was accompanied by a favorable safety profile, with no body weight loss or systemic toxicity observed.

Conclusion: BCG042 uniquely pairs targeted blockade of the LILRB4-APOE immunosuppressive axis with a potent, Fc-engineered ADCC effect. This dual mechanism of action drives superior preclinical antitumor efficacy and a broad therapeutic window compared to current clinical benchmarks, establishing a strong rationale for evaluating BCG042 as a novel therapy for relapsed/refractory monocytic AML.

Hannah Horton: No relevant conflicts of interest to declare.